AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05208203 — intervention group
Intervention type: OTHER
Intervention: telephone call d90
Description: telephone call on day 90 to assess the primary outcome (mRs d90)
Study NCT05815797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDD formula
Description: SDD formula consists of 23 herbal medicines
Study NCT05815797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05664477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PhytoSERM
Description: PhytoSERM is a dietary supplement containing equal amounts of genistein (16.7 mg ± 10%), daidzein (16.7 mg ± 10%) and S-equol (16.7 mg ± 10%).
Study NCT05664477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product with identical shape, size and color will be produced with absence of S-equol, daidzein and genistein. Ingredients include calcium carbonate, comprecel M102, croscarmellose sodium, stearic acid, Zeofree 5162, magnesium stearate, carnauba wax, coating cellulose clear (PEG), coating white (PEG), water.
Study NCT04949581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bioelectric therapy
Description: the patient will receive microcurrent therapy from a supine lying position. the negative electrode on the incision area and the positive electrode proximal. the intensity will be less than 20 microamperes and frequency at 20 HZ.
Study NCT04949581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac rehabilitation program
Description: the patient will receive cardiac rehabilitation program
Study NCT04949581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cardiac rehabilitation program
Description: the patient will receive cardiac rehabilitation program
Study NCT04065802 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radioablation
Description: External, non-invasive radiation delivery to scar regions of heart to treat ventricular arrhythmias
Study NCT05967533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fermented Wheat Germ Extract
Description: Given PO
Study NCT06519253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) music intervention
Description: The VR music intervention consists of musical performance which were already recorded. This is accessible classic music. During the intervention, the participants will be able to see the musicians (and the stage, empty auditorium, etc.) and hear the music.
Study NCT06519253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music only control
Description: The control group consists of the same musical performances, with the audio only
Study NCT05767203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samplings
Description: Blood and/or skin samples
Study NCT05466279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remazolam
Description: Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil.
Study NCT05466279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol (2,6-diisopropylphenol) is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus
Study NCT05466279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam, like diazepam, is a benzodiazepine anxiolytic drug, which is used to treat anxiety, but its t ½ is much shorter or only about 2 h compared with 43 h for diazepam
Study NCT06051084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-Delivered Mindfulness Training (MT)
Description: The program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
Study NCT06051084 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: App-Delivered Coloring
Description: An app-based coloring book with a variety of designs to choose from including mandalas, animal patterns, and florals. It is designed to help individuals relax and reduce stress and anxiety based on the benefits found in past research studies.
Study NCT05863624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open hernioplasty
Description: Inguinal hernia is operated using open surgery
Study NCT05863624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEP hernioplasty
Description: Inguinal hernia is operated using laparoendoscopic technique
Study NCT05899829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camlipixant
Description: Camlipixant will be administered
Study NCT05899829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole will be administered
Study NCT05899829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin will be administered.
Study NCT06415487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting agent
Study NCT04877314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: 30 overweight male volunteers who will have 3 weeks intermittent fasting which has 16 hours fasting and 8 hours eating in a day period.
Study NCT05946174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Set A
Description: exercise sessions and meals over approximately 12 weeks
Study NCT05946174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Set B
Description: exercise sessions and meals over approximately 3 weeks
Study NCT06017583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tirellizumab was administered intravenously at 200mg/d1, 21 days per cycle, with at least 4 cycles completed.
Study NCT06017583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Oral capecitabine 825mg/m2 bid, radiotherapy day concurrent chemotherapy. Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
Study NCT05946174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Set C
Description: meals over approximately 3 weeks
Study NCT06017583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral capecitabine 825mg/m2 bid, radiotherapy day concurrent chemotherapy. Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
Study NCT06017583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
Study NCT06017583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
Study NCT06017583 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Description: The tumor and the related mesenteric region 1cm above and below were simultaneously integrated boost to 5600cGy with the intensity-modulated radiotherapy. The other dose for clinical target volume is 5000 cGy.
Study NCT06017583 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: IMRT
Description: The whole dose of the clinical target volume is 5000 cGy with intensity-modulated radiotherapy.
Study NCT05364008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Green Tea Extract
Description: Green tea extract 1650 mg/day (45% EGCG) along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
Study NCT05364008 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1650 mg/day along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
Study NCT04966364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hypotension prediction index guided
Description: patients receiving hypotension prediction index monitoring and let the anesthesiologist' alerted the coming intraoperatiobe hypotension
Study NCT04966364 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: without hypotesion prediction index guided
Description: patients receiving usual care without hypotension prediction index monitoring but with usual arterial line care
Study NCT04817215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801
Description: Randomized to receive ORMD-0801 8 mg QD or 8 mg BID or matching placebo
Study NCT05678192 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oral menopausal hormone therapy
Description: Dydrogesterone 10 mg + Estradiol 1 mg/Dydrogesterone 5 mg + Estradiol 1 mg
Study NCT05951309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inofolic combi
Description: The patients in this group were given inofolic combi once a day for 12-16 weeks
Study NCT05678192 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: transdermal menopausal hormone therapy
Description: Estradiol 1,5 mg + Progesterone 200 mg/Estradiol 1,5 mg + Progesterone 100 mg
Study NCT05951309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage 500Mg Tablet
Description: The patients in this group were given glucophage three times a day for 12-16 weeks
Study NCT06415487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting agent
Study NCT06415487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE2016
Description: Allogeneic gamma delta T (gdT) cell therapy
Study NCT06415487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune checkpoint anti-PD-1 antibody
Study NCT06226610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: injection every two weeks while on study
Study NCT04858880 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.
Description: Radiation to the prostate bed with or without addition of radiation of lymph node irradiation (non responders). Patients with PSA response continues radiotherapy as initially planned, and are not followed according to the study protocol, only according to clinical practice.
Study NCT04858880 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.
Description: Radiation to the prostate bed with or without addition of radiation of lymph node irradiation (non responders). Patients with PSA response continues radiotherapy as initially planned, and are not followed according to the study protocol, only according to clinical practice.
Study NCT05824637 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Skin Prick Automated Test
Description: skin prick test to detection sensitisation to aeroallergens
Study NCT05824637 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Skin Prick Manual Test
Description: skin prick test to detection sensitisation to aeroallergens
Study NCT05261997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave lithotripsy and endoscopic drainage of the main pancreatic duct
Description: In addition to drug administrated in the control group, patients in this group would be treated with ESWL and endoscopic drainage of the main pancreatic duct.
Study NCT05261997 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pancreatic enzyme(Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose Tablets, Glucophage, Glimepirde Tablets)
Description: Patients will receive drugs to control pancreatic insufficiency
Study NCT06307223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% supramolecular salicylic acid
Description: The patients received weekly application of 30% supramolecular salicylic acid for a duration of 8 weeks.
Study NCT06307223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: supramolecular active zinc
Description: The patients received daily application of topical supramolecular active zinc anti-dandruff lotion for a duration of 8 weeks.
Study NCT06226610 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: injection every two weeks while on study
Study NCT05826379 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive Daily Goal Setting
Description: Daily step goals displayed by the study application
Study NCT05826379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Daily Goal Setting
Description: Daily step goals displayed by the study application
Study NCT05826379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interim Goal Prompt
Description: Short-term step goals
Study NCT05794568 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OITcontrol app monitoring
Description: App to monitor OIT patients
Study NCT04951414 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ICF core set
Description: KOA rehabilitation regimen based on the complete core combination of ICF was accepted
Study NCT06196593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof™ IQ Vivity™ Toric intraocular lens
Description: Uneventful phacoemulsification and implantation of IOL
Study NCT05082363 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: C4d evaluation in lupus nephritis in serum and renal tissue
Description: C4d plasma levels were analyzed by a unique assay specifically detecting C4d arising from complement activation and C4 plasma levels were quantified with competitive ELISA. SLE patients in activitity with and without lupus nephritis In patient with lupus nephritis we will evaluate the C4d after developing remission in the form of reduction of proteinurea less than .5g/g measured as PCR as complete response and less than50% reduction in proteinurea in partial response according to KIDGO guide line Percutaneous renal biopsies were performed in SLE and non-SLE patients under ultrasonographic guidance. 10% formalin-fixed tissue was embedded in paraffin. Four μm-thick sections were stained with hematoxylin and eosin (H\&E), periodic acid-Schiff (PAS), periodic acid methenamine silver (PAM), masson-trichrome and polyclonal rabbit anti-human C4d antibody, Renal biopsy specimens of SLE patients were assessed using the most recent modification of the World Health Organization (WHO)
Study NCT05915286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
Study NCT05915286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Description: Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
Study NCT05595928 — intervention group
Intervention type: OTHER
Intervention: position
Description: To compare whether there is a difference between maternal and fetal effects of Supine, 15-degree left tilt, and 30-degrees left tilt.
Study NCT05558384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: A 15-week standardized aerobic exercise intervention.~* Frequency: 5 days/wk (2 supervised)~* Intensity: 50-59% heart rate reserve~* Time: 40 min/session (ramp up from 25-40 during first 4 weeks)~* Type: Aerobic exercise (e.g. treadmill, walking/jogging, cycling, elliptical)
Study NCT06108687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water spray application
Description: cold water kept in the refrigerator at +4 degrees
Study NCT05207813 — intervention group
Intervention type: DEVICE
Intervention: Intracept Procedure
Description: Intraosseous Basivertebral Nerve (BVN) Ablation
Study NCT04252235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air purifier
Description: The intervention is the placement of active HEPA air purifiers in the bedroom and living room of the true air purifier arm. These air purifiers have been shown to reduce levels of particles in the home.
Study NCT04252235 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham air purifier
Description: The intervention is the placement of sham HEPA air purifiers in the bedroom and living room. These purifiers look identical to real HEPA air purifiers, but do not filter the air.
Study NCT06482567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCOVER
Description: The term iCOVER is an acronym that summarizes the six specific steps of the intervention: (1) identify that an individual is experiencing an ASR; (2) Connect with the individual through word, eye contact, and physical touch to draw them back to the present moment; (3) Offer commitment so that the individual feels less psychologically isolated and withdrawn (e.g., I'm right here with you); (4) Verify facts - ask simple fact-based questions to engage the individual in deliberate cognitive activity; (5) Establish order of events - briefly review what has happened, what is happening, and what will happen to orient the individual; and (6) Request action to re-engage the individual in purposeful behavior.
Study NCT06482567 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Presence with Reassurance
Description: The RA who performed randomization, initially approached the individual, and obtained assent will stay with the participant for the length of the iCOVER intervention (in order to ensure matching of the amount of time spent with individuals who receive the iCOVER intervention, which takes 60-120 seconds). During this time, the RA will provide supportive but passive statements. The RA will leave the participant after the length of the iCOVER intervention has elapsed. A separate blinded RA will return 5 minutes post-intervention to conduct the immediate post-intervention assessment.
Study NCT06040541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-9805
Description: Oral Tablets
Study NCT06040541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6236
Description: Oral Tablets
Study NCT06290388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 23ME-01473
Description: 23Me-01473 given by intravenous infusion
Study NCT06225466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: After induction of anesthesia and placement of an IV, rocuronium 0.6 mg/kg (maximum dose 50mg) will be administered. Additional doses of rocuronium 0.2 mg/kg (maximum dose 15 mg) will be administered when the neuromuscular transmission monitor indicates a train of four count of 2 or greater.
Study NCT06225466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: When the surgery is completed, sugammadex 2 mg/kg will be administered if the neuromuscular transmission monitor indicates the train of four count is 2 or greater. Sugammadex 4 mg/kg will be administered if 1) the train of four count is 1, or 2) if the train of four count is 0 and the post tetanic count is at least 1. There is no maximum dose of sugammadex.
Study NCT06225466 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anesthesia without neuromuscular blockade
Description: Anesthesia without rocuronium or sugammadex
Study NCT05672966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human papillomavirus (HPV) Vaccine
Description: 0.5mL, Intramuscular
Study NCT05672966 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5mL, Intramuscular
Study NCT05478330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide 1% gel
Description: Group A: Flutamide-treated patients: Consisted of 25 patients with acne vulgaris treated with 1% Flutamide topical gel on the face two times per day for a duration of 8 weeks.
Study NCT05478330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topical gel without flutamide
Description: Group B: Consisted of 25 patients with acne vulgaris treated with topical gel with the same component as the other group, except for flutamide, on the face twice per day for a duration of 8 weeks.
Study NCT05089526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine-lidocaine-dexmedetomidine
Description: In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution.
Study NCT05089526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.